-
T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy JAMA Oncol. (IF 28.4) Pub Date : 2024-04-18 Ryan Storgard, Kai Rejeski, Miguel-Angel Perales, Adam Goldman, Roni Shouval
This cohort study assesses the increase in second primary malignant neoplasms and T-cell malignant neoplasm cases associated with chimeric antigen receptor–T cells.
-
Policy Priorities in Cancer Care for Transgender People JAMA Oncol. (IF 28.4) Pub Date : 2024-04-18 Alicia C. Smart, Michael J. Yunes, Karen M. Winkfield
This Viewpoint calls for health care systems, oncologists, and staff to prioritize and adopt policies that are inclusive and respectful of transgender patients with cancer.
-
Adherence to American Cancer Society Nutrition and Physical Activity Guidelines Among Cancer Survivors JAMA Oncol. (IF 28.4) Pub Date : 2024-04-18 Carter Baughman, Kathryn Norman, Kenneth Mukamal
ImportanceThe American Cancer Society’s (ACS’s) nutrition and physical activity guidelines are intended to reduce morbidity and mortality among cancer survivors, but to our knowledge, adherence to these guidelines has not been systematically quantified.ObjectiveTo evaluate adherence to and factors associated with adherence to lifestyle modification guidelines among cancer survivors.Design, Setting
-
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia JAMA Oncol. (IF 28.4) Pub Date : 2024-04-18 Laurent Phely, Luca Hensen, Christoph Faul, Christer Alexander Ruff, Dina Schneider, Wolfgang Andreas Bethge, Claudia Lengerke
This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.
-
Patient-Reported Outcomes as a Recruitment Strategy for Clinical Trial Enrollment JAMA Oncol. (IF 28.4) Pub Date : 2024-04-11 Nicholas P. Verdini, Karolina L. Bryl, Raymond E. Baser, Kaitlyn Lapen, Jun J. Mao, Erin F. Gillespie
ImportanceClinical trials are critical for progress in oncology; however, only 5% of the adult cancer population participates. Harnessing data that are routinely collected (ie, electronic patient-reported outcomes [ePROs]) may serve as a method to promote trial enrollment.ObjectiveTo evaluate if an ePRO-prompted recruitment strategy is associated with increased clinical trial enrollment.Design, Setting
-
American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-04-11 George Rodrigues, Kristin A. Higgins, Andreas Rimner, Arya Amini, Joe Y. Chang, Stephen G. Chun, Jessica Donington, Martin J. Edelman, Matthew A. Gubens, Puneeth Iyengar, Benjamin Movsas, Matthew S. Ning, Henry S. Park, Andrea Wolf, Charles B. Simone
ImportanceThe treatment of locally advanced non–small cell lung cancer (LA-NSCLC) has been informed by more than 5 decades of clinical trials and other relevant literature. However, controversies remain regarding the application of various radiation and systemic therapies in commonly encountered clinical scenarios.ObjectiveTo develop case-referenced consensus and evidence-based guidelines to inform
-
Second Primary Breast Cancer in Young Breast Cancer Survivors JAMA Oncol. (IF 28.4) Pub Date : 2024-04-11 Kristen D. Brantley, Shoshana M. Rosenberg, Laura C. Collins, Kathryn J. Ruddy, Rulla M. Tamimi, Lidia Schapira, Virginia F. Borges, Ellen Warner, Steven E. Come, Yue Zheng, Gregory J. Kirkner, Craig Snow, Eric P. Winer, Ann H. Partridge
ImportanceAmong women diagnosed with primary breast cancer (BC) at or younger than age 40 years, prior data suggest that their risk of a second primary BC (SPBC) is higher than that of women who are older when they develop a first primary BC.ObjectiveTo estimate cumulative incidence and characterize risk factors of SPBC among young patients with BC.Design, Setting, and ParticipantsParticipants were
-
Magnetic Resonance Imaging in Prostate Cancer Screening JAMA Oncol. (IF 28.4) Pub Date : 2024-04-05 Tamás Fazekas, Sung Ryul Shim, Giuseppe Basile, Michael Baboudjian, Tamás Kói, Mikolaj Przydacz, Mohammad Abufaraj, Guillaume Ploussard, Veeru Kasivisvanathan, Juan Gómez Rivas, Giorgio Gandaglia, Tibor Szarvas, Ivo G. Schoots, Roderick C. N. van den Bergh, Michael S. Leapman, Péter Nyirády, Shahrokh F. Shariat, Pawel Rajwa
ImportanceProstate magnetic resonance imaging (MRI) is increasingly integrated within the prostate cancer (PCa) early detection pathway.ObjectiveTo systematically evaluate the existing evidence regarding screening pathways incorporating MRI with targeted biopsy and assess their diagnostic value compared with prostate-specific antigen (PSA)–based screening with systematic biopsy strategies.Data SourcesPubMed/MEDLINE
-
Ovarian Cancer Isn’t Just a White Woman’s Disease JAMA Oncol. (IF 28.4) Pub Date : 2024-04-04 Anna Jo Bodurtha Smith, Elizabeth A. Howell, Emily M. Ko
This Viewpoint highlights the need for recognition that ovarian cancer affects women from racial and ethnic minority groups worldwide and that the rates of ovarian cancer are increasing in those populations while decreasing among White women.
-
Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies JAMA Oncol. (IF 28.4) Pub Date : 2024-04-04 Ariadna Tibau, Thomas J. Hwang, Consolacion Molto, Jerry Avorn, Aaron S. Kesselheim
ImportanceThe number of new genome-targeted cancer drugs has increased, offering the possibility of personalized therapy, often at a very high cost.ObjectiveTo assess the validity of molecular targets and therapeutic benefits of US Food and Drug Administration–approved genome-targeted cancer drugs based on the outcomes of their corresponding pivotal clinical trials.Design and SettingsIn this cohort
-
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-03-28 Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, Tomás Pascual, Katherine A. Hoadley, David Venet, Naim U. Rashid, Patricia A. Spears, Md N. Islam, Sarra El-Abed, Judith Bliss, Matteo Lambertini, Serena Di Cosimo, Jens Huobe, David Goerlitz, Rong Hu, Peter C. Lucas, Sandra M. Swain, Christos Sotiriou, Charles M. Perou, Lisa A. Carey
ImportanceBiologic features may affect pathologic complete response (pCR) and event-free survival (EFS) after neoadjuvant chemotherapy plus ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer (EBC).ObjectiveTo define the quantitative association between pCR and EFS by intrinsic subtype and by other gene expression signatures in a pooled analysis of 3 phase 3 trials: CALGB 40601, NeoALTTO
-
Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma JAMA Oncol. (IF 28.4) Pub Date : 2024-03-28 Ankit Mangla, Chanmi Lee, Matthew M. Mirsky, Margaret Wang, Luke D. Rothermel, Richard Hoehn, Jeremy S. Bordeaux, Bryan T. Carrol, Jason Theuner, Shawn Li, Pingfu Fu, John M. Kirkwood
ImportanceDespite the clear potential benefits of neoadjuvant therapy, the optimal neoadjuvant regimen for patients with high-risk resectable melanoma (HRRM) is not known.ObjectiveTo compare the safety and efficacy of dual checkpoint inhibitors with anti–programmed cell death protein-1 (anti-PD1) therapy in a neoadjuvant setting among patients with HRRM.Design, Setting, and ParticipantsIn this pooled
-
Physical Activity Using a Wearable Device as an Alternative to Performance Status in Patients With Advanced Lung Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-03-28 Kentaro Ito, Yuta Suzuki, Tadashi Sakaguchi, Kentaro Fujiwara, Yoichi Nishii, Hiroki Yasui, Osamu Taguchi, Osamu Hataji
ImportanceThe Eastern Cooperative Oncology Group Performance Status (ECOG PS) is extensively used to guide treatment decisions in patients with advanced lung cancer. However, its assessment is subjective, potentially leading to discordance among observers.ObjectiveTo investigate the association between measured physical activity and ECOG PS, as well as the potential prognostic value of physical activity
-
Cancer Care in the Era of Artificial Intelligence JAMA Oncol. (IF 28.4) Pub Date : 2024-03-28 Matthew Kurian, Jacob J. Adashek, Howard (Jack) West
This JAMA Oncology Patient Page explains artifical intelligence and what patients should know about how it can be used in oncology.
-
Machine Learning–Based Prediction of Hospitalization During Chemoradiotherapy With Daily Step Counts JAMA Oncol. (IF 28.4) Pub Date : 2024-03-28 Isabel D. Friesner, Jean Feng, Shalom Kalnicki, Madhur Garg, Nitin Ohri, Julian C. Hong
ImportanceToxic effects of concurrent chemoradiotherapy (CRT) can cause treatment interruptions and hospitalizations, reducing treatment efficacy and increasing health care costs. Physical activity monitoring may enable early identification of patients at high risk for hospitalization who may benefit from proactive intervention.ObjectiveTo develop and validate machine learning (ML) approaches based
-
Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time JAMA Oncol. (IF 28.4) Pub Date : 2024-03-21 Hassal Lee, Alexander Shakeel Bates, Shawneequa Callier, Michael Chan, Nyasha Chambwe, Andrea Marshall, Mary Beth Terry, Karen Winkfield, Tobias Janowitz
ImportanceRacially minoritized and socioeconomically disadvantaged populations are currently underrepresented in clinical trials. Data-driven, quantitative analyses and strategies are required to help address this inequity.ObjectiveTo systematically analyze the geographical distribution of self-identified racial and socioeconomic demographics within commuting distance to cancer clinical trial centers
-
PARP Inhibitors for Breast Cancer Treatment JAMA Oncol. (IF 28.4) Pub Date : 2024-03-21 Stefania Morganti, Antonio Marra, Carmine De Angelis, Angela Toss, Luca Licata, Federica Giugliano,, Beatrice Taurelli Salimbeni, Pier Paolo Maria Berton Giachetti, Angela Esposito, Antonio Giordano, Giampaolo Bianchini, Judy E. Garber, Giuseppe Curigliano, Filipa Lynce, Carmen Criscitiello
ImportancePoly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors have revolutionized the treatment of patients with germline BRCA1/2-associated breast cancer, representing the first targeted therapy capable of improving outcomes in patients with hereditary tumors. However, resistance to PARP inhibitors occurs in almost all patients.ObservationsThis narrative review summarizes the biological
-
The Ethics of Hope—A Moral Imperative for Oncologists JAMA Oncol. (IF 28.4) Pub Date : 2024-03-21 Benjamin W. Corn, David B. Feldman
This Viewpoint suggests that giving patients with terminal cancer unrealistic hope based only on cure is ethically inferior to redirecting patients toward noncurative goals and noncancer-related hope.
-
Neoadjuvant Chemoimmunotherapy for NSCLC JAMA Oncol. (IF 28.4) Pub Date : 2024-03-21 Mark Sorin, Connor Prosty, Louis Ghaleb, Kathy Nie, Khaled Katergi, Muhammad H. Shahzad, Laurie-Rose Dubé, Aline Atallah, Anikka Swaby, Matthew Dankner, Trafford Crump, Logan A. Walsh, Pierre O. Fiset, Boris Sepesi, Patrick M. Forde, Tina Cascone, Mariano Provencio, Jonathan D. Spicer
ImportanceTo date, no meta-analyses have comprehensively assessed the association of neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer (NSCLC) in randomized and nonrandomized settings. In addition, there exists controversy concerning the efficacy of neoadjuvant chemoimmunotherapy for patients with NSCLC with programmed cell death 1 ligand 1 (PD-L1) levels less than
-
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms JAMA Oncol. (IF 28.4) Pub Date : 2024-03-14 Mark K. Buyyounouski, Stephanie L. Pugh, Ronald C. Chen, Mark J. Mann, Rajat J. Kudchadker, Andre A. Konski, Omar Y. Mian, Jeff M. Michalski, Eric Vigneault, Richard K. Valicenti, Maroie Barkati, Colleen A. F. Lawton, Louis Potters, Drew C. Monitto, Jeffrey A. Kittel, Thomas M. Schroeder, Raquibul Hannan, Casey E. Duncan, Joseph P. Rodgers, Felix Feng, Howard M. Sandler
ImportanceNo prior trial has compared hypofractionated postprostatectomy radiotherapy (HYPORT) to conventionally fractionated postprostatectomy (COPORT) in patients primarily treated with prostatectomy.ObjectiveTo determine if HYPORT is noninferior to COPORT for patient-reported genitourinary (GU) and gastrointestinal (GI) symptoms at 2 years.Design, Setting, and ParticipantsIn this phase 3 randomized
-
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-03-07 Daniel E. Spratt, Daniel J. George, Neal D. Shore, Michael S. Cookson, Daniel R. Saltzstein, Ronald Tutrone, Alberto Bossi, Bruce A. Brown, Sophia Lu, Mark Fallick, Sarah Hanson, Bertrand F. Tombal
ImportanceCombination androgen deprivation therapy (ADT) with radiotherapy is commonly used for patients with localized and advanced prostate cancer.ObjectiveTo assess the efficacy and safety of the oral gonadotropin-releasing hormone antagonist relugolix with radiotherapy for treating prostate cancer.Design, Setting, and ParticipantsThis multicenter post hoc analysis of patients with localized and
-
Charting the Path to Systemic Therapy De-escalation—Oligometastatic Kidney Cancer as a Paradigm JAMA Oncol. (IF 28.4) Pub Date : 2024-03-07 Chad Tang, Pavlos Msaouel
This Viewpoint discusses whether select patient populations may benefit from de-escalation rather than escalation of systemic therapy for kidney cancer.
-
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-03-07 Yoko Tsukita, Takehiro Tozuka, Kohei Kushiro, Shinobu Hosokawa, Toshiyuki Sumi, Mao Uematsu, Osamu Honjo, Ou Yamaguchi, Tetsuhiko Asao, Jun Sugisaka, Go Saito, Jun Shiihara, Ryo Morita, Seigo Katakura, Takehiro Yasuda, Kakeru Hisakane, Eisaku Miyauchi, Satoshi Morita, Kunihiko Kobayashi, Hajime Asahina
ImportanceImmune checkpoint inhibitor (ICI) plus chemotherapy combination treatment (ICI-chemotherapy) is now a standard treatment for non–small cell lung cancer (NSCLC) without targetable oncogene alterations, but there are few data on ICI-chemotherapy for patients 75 years and older.ObjectiveTo inform the choice of first-line drugs in clinical practice and assess the safety and efficacy of ICI-chemotherapy
-
Stereotactic Radiation Therapy in Early Non–Small Cell Lung Cancer and Interstitial Lung Disease JAMA Oncol. (IF 28.4) Pub Date : 2024-03-07 David A. Palma, Houda Bahig, Andrew Hope, Stephen Harrow, Brock J. Debenham, Alexander V. Louie, Thi Trinh Thuc (Toni) Vu, Edith Filion, Andrea Bezjak, Marie-Pierre Campeau, Adele Duimering, Meredith E. Giuliani, Joanna M. Laba, Pencilla Lang, Benjamin H. Lok, X. Melody Qu, Srinivas Raman, George B. Rodrigues, Christopher D. Goodman, Stewart Gaede, Julie Morisset, Andrew Warner, Inderdeep Dhaliwal
ImportancePatients with interstitial lung disease (ILD) and early-stage non–small cell lung cancer (NSCLC) have been reported to be at high risk of toxic effects after stereotactic ablative radiotherapy (SABR), but for many patients, there are limited alternative treatment options.ObjectiveTo prospectively assess the benefits and toxic effects of SABR in this patient population.Design, Setting, and
-
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-02-29 Julieta Leone, Michael J. Hassett, Rachel A. Freedman, Sara M. Tolaney, Noah Graham, Nabihah Tayob, Carlos T. Vallejo, Eric P. Winer, Nancy U. Lin, José P. Leone
ImportanceIn women with hormone receptor–positive (HR+) breast cancer, the risk of distant recurrence and death persists for at least 20 years from diagnosis. The risk of late mortality in men with HR+ breast cancer has not been reported.ObjectiveTo report 20-year risks of breast cancer–specific mortality (BCSM) and non-BCSM in men with stage I to III HR+ breast cancer and identify factors associated
-
Accreditation Standards—An Untapped Lever for Cancer Equity JAMA Oncol. (IF 28.4) Pub Date : 2024-02-22 Parsa Erfani, Nishant Uppal, Miranda B. Lam
This Viewpoint describes how the Commission on Cancer and the National Cancer Institute can incorporate health equity benchmarks into existing standards to improve care and outcomes for all patients with cancer.
-
Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy JAMA Oncol. (IF 28.4) Pub Date : 2024-02-22 Mark Gurney, Anmol Baranwal, Allison Rosenthal, Mohamed A. Kharfan-Dabaja, Saad S. Kenderian, Yi Lin, Mithun Vinod Shah
This case-control study examines the incidence and risks of myeloid neoplasms in adults treated for B-cell lymphoproliferative disorders or multiple myeloma.
-
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic JAMA Oncol. (IF 28.4) Pub Date : 2024-02-22 Todd Burus, Feitong Lei, Bin Huang, W. Jay Christian, Pamela C. Hull, Amanda R. Ellis, Svetla Slavova, Thomas C. Tucker, Krystle A. Lang Kuhs
ImportanceThe COVID-19 pandemic disrupted the normal course of cancer screening and detection in the US. A nationwide analysis of the extent of this disruption using cancer registry data has not been conducted.ObjectiveTo assess the observed and expected cancer rate trends for March through December 2020 using data from all 50 US states and the District of Columbia.Design, Settings, and ParticipantsThis
-
Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access JAMA Oncol. (IF 28.4) Pub Date : 2024-02-15 Craig Underhill, Jessica Freeman, Jacqueline Dixon, Mark Buzza, Donna Long, Kate Burbury, Sabe Sabesan, Jacqueline McBurnie, Anne Woollett
ImportanceThe need to maintain clinical trial recruitment during the COVID-19 pandemic has precipitated the rapid uptake of digital health for the conduct of clinical trials. Different terms are used in different jurisdictions and clinical contexts, including digital trials, networked trials, teletrials (TT), and decentralized clinical trials (DCT) with a need to agree to terms.ObservationsThis clinical
-
Response to 2 Induction Courses of Bacillus Calmette-Guèrin Therapy Among Patients With High-Risk Non–Muscle-Invasive Bladder Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-02-15 Andrew B. Katims, Jacob Tallman, Emily Vertosick, Shaun Porwal, Guido Dalbagni, Eugene K. Cha, Robert Smith, Nicole Benfante, Harry W. Herr
ImportanceWith the ongoing bacillus Calmette-Guèrin (BCG) shortage, alternate therapeutic options for patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are needed.ObjectiveTo report the 5-year outcomes of a cohort from a prospective phase 2 trial of patients with high-risk NMIBC who underwent 12 instillations of induction BCG without maintenance.Design, Setting, and ParticipantsBetween
-
Modernize Precision Oncology With Decentralized Trial Tools JAMA Oncol. (IF 28.4) Pub Date : 2024-02-15 Muhammad Shaalan Beg, Vivek Subbiah
This Viewpoint examines how modern precision oncology clinical trials, bolstered by decentralized trial tools, can enhance access to cancer treatments and reduce the burden of trial participation on clinics and participants.
-
Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma JAMA Oncol. (IF 28.4) Pub Date : 2024-02-08 Jinxuan Dai, Bin Zhang, Yixin Su, Yufei Pan, Zhenkai Ye, Rui Cai, Guanjie Qin, Xiangyun Kong, Yunyan Mo, Rongjun Zhang, Zhengchun Liu, Yuan Xie, Xiaolan Ruan, Wei Jiang
ImportanceInduction chemotherapy plus concurrent chemoradiotherapy is recommended for locoregionally advanced nasopharyngeal carcinoma but is associated with higher rates of acute toxic effects and low compliance. Evidence on de-escalating treatment intensity after induction chemotherapy is limited.ObjectiveTo assess if radiotherapy was noninferior to chemoradiotherapy after induction chemotherapy
-
Hyperbaric Oxygen Therapy and Late Local Toxic Effects in Patients With Irradiated Breast Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-02-08 Dieuwke R. Mink van der Molen, Marilot C. T. Batenburg, Wiesje Maarse, Desiree H. J. G. van den Bongard, Annemiek Doeksen, Marjoleine Y. de Lange, Carmen C. van der Pol, Daniel J. Evers, Corine A. Lansdorp, Jacco van der Laan, Peter M. van de Ven, Femke van der Leij, Helena M. Verkooijen
ImportanceHyperbaric oxygen therapy (HBOT) is proposed as treatment for late local toxic effects after breast irradiation. Strong evidence of effectiveness is lacking.ObjectiveTo assess effectiveness of HBOT for late local toxic effects in women who received adjuvant radiotherapy for breast cancer.Design, Setting, and ParticipantsThis was a hospital-based, pragmatic, 2-arm, randomized clinical trial
-
The Threat of Florida’s New Legislation on Undocumented Individuals—A Call for Action JAMA Oncol. (IF 28.4) Pub Date : 2024-02-08 Coral Olazagasti
This essay describes the author’s experience with a patient that illustrates what undocumented individuals living in Florida are experiencing due to Bill 1718.
-
Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition JAMA Oncol. (IF 28.4) Pub Date : 2024-02-08 Peter D. Zang, Neal S. Chawla, Regina Barragan-Carrillo, Alex Chehrazi-Raffle, Abhishek Tripathi, Sumanta K. Pal, Tanya B. Dorff
This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.
-
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases JAMA Oncol. (IF 28.4) Pub Date : 2024-02-08 Shaohua Zhang, Yongmei Yin, Hailin Xiong, Jingfen Wang, Hu Liu, Junguo Lu, Qingyuan Zhang, Longzhen Zhang, Jincai Zhong, Jianyun Nie, Kaijian Lei, Hong Wang, Shu Yang, Herui Yao, Huijing Wu, Ding Yu, Xuening Ji, Hua Zhang, Fang Wu, Weimin Xie, Wei Li, Weirong Yao, Diansheng Zhong, Hongmei Sun, Tao Sun, Zengqing Guo, Rui Wang, Yanzhen Guo, Zhuang Yu, Dairong Li, Hongyan Jin, Haifeng Song, Xiaoyuan Chen
ImportanceThe bioequivalence of denosumab biosimilar has yet to be studied in a 53-week, multicenter, large-scale, and head-to-head trial. A clinically effective biosimilar may help increase access to denosumab in patients with solid tumor–related bone metastases.ObjectivesTo establish the biosimilarity of MW032 to denosumab in patients with solid tumor–related bone metastases based on a large-scale
-
Association of Skin Microbiome Dynamics With Radiodermatitis in Patients With Breast Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-02-01 Claudia Hülpüsch, Avidan Uriel Neumann, Matthias Reiger, Julius Clemens Fischer, Amedeo de Tomassi, Gertrud Hammel, Carina Gülzow, Megan Fleming, Hendrik Dapper, Michael Mayinger, Marco Vogel, Christina Ertl, Stephanie Elisabeth Combs, Claudia Traidl-Hoffmann, Kai Joachim Borm
ImportanceThe interindividual differences in severity of acute radiation dermatitis are not well understood. To date, the pathomechanism and interplay of microbiome and radiodermatitis before and during treatment remain largely unknown.ObjectiveTo assess the association of skin microbiome baseline composition and dynamics with severity of radiodermatitis in patients undergoing adjuvant radiotherapy
-
Investigation of Genetic Alterations Associated With Interval Breast Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-01-25 Juan Rodriguez, Felix Grassmann, Qingyang Xiao, Mikael Eriksson, Xinhe Mao, Svetlana Bajalica-Lagercrantz, Per Hall, Kamila Czene
ImportanceBreast cancers (BCs) diagnosed between 2 screening examinations are called interval cancers (ICs), and they have worse clinicopathological characteristics and poorer prognosis than screen-detected cancers (SDCs). However, the association of rare germline genetic variants with IC have not been studied.ObjectiveTo evaluate whether rare germline deleterious protein-truncating variants (PTVs)
-
Efficacy of Tixagevimab-Cilgavimab as Immunoprophylaxis in Patients With Hematologic Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-01-25 Marco Salvini, Paolo Antonio Grossi, Alessandro Cacioppo, Michele Merli, Giacomo Pellegrini, Marco Brociner, Francesco Passamonti
This cohort study compares outcomes for patients with hematologic malignant tumors who prophylactically received tixagevimab-cilgavimab against SARS-CoV-2 with those who did not.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination JAMA Oncol. (IF 28.4) Pub Date : 2024-01-18 Cynthia X. Ma, Vera J. Suman, Souzan Sanati, Kiran Vij, Meenakshi Anurag, A. Marilyn Leitch, Gary W. Unzeitig, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard A. Gibbs, Mark A. Watson, Travis J. Dockter, Olwen Hahn, Joseph M. Guenther, Abigail Caudle, Erika Crouch, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, Mothaffar F. Rimawi, Anna Weiss, Eric P. Winer, Kelly
ImportanceAdding fulvestrant to anastrozole (A+F) improved survival in postmenopausal women with advanced estrogen receptor (ER)–positive/ERBB2 (formerly HER2)–negative breast cancer. However, the combination has not been tested in early-stage disease.ObjectiveTo determine whether neoadjuvant fulvestrant or A+F increases the rate of pathologic complete response or ypT1-2N0/N1mic/Ki67 2.7% or less residual
-
Out-of-Pocket Costs and Outpatient Visits Among Patients With Cancer in High-Deductible Health Plans JAMA Oncol. (IF 28.4) Pub Date : 2024-01-18 Nicolas K. Trad, Fang Zhang, James Franklin Wharam
ImportanceHigh-deductible health plans (HDHPs) have grown rapidly and may adversely affect access to comprehensive cancer care.ObjectiveTo evaluate the association of HDHPs with out-of-pocket medical costs and outpatient physician visits among patients with cancer.Design, Setting, and ParticipantsUsing 2003 to 2017 data from the deidentified Optum Clinformatics Data Mart database from individuals with
-
The Case for Allowing Proton Beam Therapy on Head and Neck Cooperative Group Studies JAMA Oncol. (IF 28.4) Pub Date : 2024-01-11 Neal S. McCall, Steven J. Frank, William A. Stokes
This Viewpoint present the case for revisiting the proscription of proton beam therapy in trials of patients with de novo, nonmetastatic head and neck cancer.
-
Substance Use Disorders Among US Adult Cancer Survivors JAMA Oncol. (IF 28.4) Pub Date : 2024-01-11 Katie F. Jones, Oyomoare L. Osazuwa-Peters, Andrea Des Marais, Jessica S. Merlin, Devon K. Check
ImportanceSome individuals are predisposed to cancer based on their substance use history, and others may use substances to manage cancer-related symptoms. Yet the intersection of substance use disorder (SUD) and cancer is understudied. Because SUD may affect and be affected by cancer care, it is important to identify cancer populations with a high prevalence of SUD, with the goal of guiding attention
-
Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non–Small Cell Lung Cancer JAMA Oncol. (IF 28.4) Pub Date : 2024-01-11 Trudy C. Wu, Elaine Luterstein, Beth K. Neilsen, Jonathan W. Goldman, Edward B. Garon, Jay M. Lee, Carol Felix, Minsong Cao, Stephen E. Tenn, Daniel A. Low, Patrick A. Kupelian, Michael L. Steinberg, Percy Lee
ImportanceIntrathoracic progression remains the predominant pattern of failure in patients treated with concurrent chemoradiation followed by a consolidation immune checkpoint inhibitor for locally advanced, unresectable non–small cell lung cancer (NSCLC).ObjectiveTo determine the maximum tolerated dose (MTD) and use of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative
-
Mirtazapine as Appetite Stimulant in Patients With Non–Small Cell Lung Cancer and Anorexia JAMA Oncol. (IF 28.4) Pub Date : 2024-01-11 Oscar Arrieta, Daniela Cárdenas-Fernández, Oscar Rodriguez-Mayoral, Salvador Gutierrez-Torres, Diana Castañares, Diana Flores-Estrada, Edgar Reyes, Dennis López, Pablo Barragán, Pamela Soberanis Pina, Andres F. Cardona, Jenny G. Turcott
ImportanceCurrently there is no standard therapy to improve cancer-related anorexia, hampering survival. Mirtazapine has been suggested as a feasible option in this context.ObjectivesTo assess the effect of mirtazapine on appetite and energy consumption in patients with advanced non–small cell lung cancer (NSCLC).Design, Setting, and ParticipantsThis randomized, double-blind, placebo-controlled clinical
-
Review of Racial and Ethnic Representation of Participants Enrolled in Pediatric Clinical Trials of Oncology Drugs Conducted Through FDA Written Requests JAMA Oncol. (IF 28.4) Pub Date : 2024-01-04 Lola A. Fashoyin-Aje, Alemayehu Y. Akalu, Jessica Boehmer, Richard Pazdur, Martha Donoghue, Gregory H. Reaman
ImportanceThe Best Pharmaceuticals for Children Act states that in issuing a written request (WR), the US Food and Drug Administration (FDA) shall consider the adequate representation (eg, proportionate to the disease population) of children from racial and ethnic minority populations. If the terms of the WR are fulfilled, the FDA may grant an additional 6 months of exclusivity for any unexpired patents
-
Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases JAMA Oncol. (IF 28.4) Pub Date : 2024-01-04 Zhaozhi Yang, Jin Meng, Xin Mei, Miao Mo, Qin Xiao, Xu Han, Li Zhang, Wei Shi, Xingxing Chen, Jinli Ma, Joshua Palmer, Zhimin Shao, Zhen Zhang, Xiaoli Yu, Xiaomao Guo
ImportanceThe potential benefit of combining intracranial effective systemic therapy with radiotherapy for patients with breast cancer with brain metastases remains unclear.ObjectiveTo assess the activity and safety of combining radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive breast cancer and brain metastases.Design, Setting, and ParticipantsThis was a single-arm, single-center
-
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US JAMA Oncol. (IF 28.4) Pub Date : 2024-01-04 Daniel M. Kerekes, Alexander E. Frey, Elizabeth H. Prsic, Thuy T. Tran, James E. Clune, Mario Sznol, Harriet M. Kluger, Howard P. Forman, Robert D. Becher, Kelly L. Olino, Sajid A. Khan
ImportanceWhile immunotherapy is being used in an expanding range of clinical scenarios, the incidence of immunotherapy initiation at the end of life (EOL) is unknown.ObjectiveTo describe patient characteristics, practice patterns, and risk factors concerning EOL-initiated (EOL-I) immunotherapy over time.Design, Setting, and ParticipantsRetrospective cohort study using a US national clinical database
-
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-30 Kuniko Sunami,Yoichi Naito,Yusuke Saigusa,Toraji Amano,Daisuke Ennishi,Mitsuho Imai,Hidenori Kage,Masashi Kanai,Hirotsugu Kenmotsu,Keigo Komine,Takafumi Koyama,Takahiro Maeda,Sachi Morita,Daisuke Sakai,Makoto Hirata,Mamoru Ito,Toshiyuki Kozuki,Hiroyuki Sakashita,Hidehito Horinouchi,Yusuke Okuma,Atsuo Takashima,Toshio Kubo,Shuichi Hironaka,Yoshihiko Segawa,Yoshihiro Yakushijin,Hideaki Bando,Akitaka
Importance Substantial heterogeneity exists in treatment recommendations across molecular tumor boards (MTBs), especially for biomarkers with low evidence levels; therefore, the learning program is essential. Objective To determine whether a learning program sharing treatment recommendations for biomarkers with low evidence levels contributes to the standardization of MTBs and to investigate the efficacy
-
Structural Racism and Lung Cancer Risk: A Scoping Review. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-30 Sidra N Bonner,Richard Curley,Kyra Love,Tola Akande,Aamna Akhtar,Loretta Erhunmwunsee
Importance Structural racism is associated with persistent inequities in health and health outcomes in the US for racial and ethnic minority groups. This review summarizes how structural racism contributes to differential population-level exposure to lung cancer risk factors and thus disparate lung cancer risk across different racial and ethnic groups. Observations A scoping review was conducted focusing
-
Contemporary Trends in Reviewing Test Results Through the Electronic Patient Portal Among Patients With Cancer. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-30 Sheena Bhalla,Tanushree Prasad,Donglu Xie,David E Gerber
-
Expanding Access to High-Quality Cancer Care Through Policy-California Cancer Care Equity Act. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Adrian Diaz,Andrew Loehrer,Timothy M Pawlik
-
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Priyanka Sharma,Shane R Stecklein,Rachel Yoder,Joshua M Staley,Kelsey Schwensen,Anne O'Dea,Lauren Nye,Deepti Satelli,Gregory Crane,Rashna Madan,Maura F O'Neil,Jamie Wagner,Kelsey E Larson,Christa Balanoff,Lyndsey Kilgore,Milind A Phadnis,Andrew K Godwin,Roberto Salgado,Qamar J Khan,Joyce O'Shaughnessy
Importance Addition of pembrolizumab to anthracycline-based chemotherapy improves pathologic complete response (pCR) and event-free survival (EFS) in triple-negative breast cancer (TNBC). The efficacy of anthracycline-free chemoimmunotherapy in TNBC has not been assessed. Objective To assess the efficacy of the anthracycline-free neoadjuvant regimen of carboplatin and docetaxel plus pembrolizumab in
-
Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns? JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Victoria E Wang,Justin F Gainor
-
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Layla Parast,Lu Tian,Lee-Jen Wei
-
Mortality and Hospitalization Risks in Patients With Cancer and the SARS-CoV-2 Omicron Variant. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Jonathan Ofer,Genady Drozdinsky,Bar Basharim,Adi Turjeman,Noa Eliakim-Raz,Salomon M Stemmer
-
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Oliver Klein
-
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Yusuke Okuma,Kaoru Kubota,Mototsugu Shimokawa,Kana Hashimoto,Yosuke Kawashima,Tomohiro Sakamoto,Hiroshi Wakui,Shuji Murakami,Kyoichi Okishio,Kenji Hayashihara,Yuichiro Ohe,
Importance Non-small cell lung cancer (NSCLC) with uncommon EGFR mutations is a rare subgroup, composing 14% of all EGFR mutations. Objective To determine the usefulness of osimertinib in previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion mutations. Design, Setting, and Participants This multicenter, open-label, single-group, phase 2 nonrandomized
-
Distribution of Cancer Care Resources Across US Hospitals by Patient Race and Ethnicity. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-16 Gracie Himmelstein,Patricia A Ganz
-
Immunotherapy in Prepatients-Preventing or Promoting a Malignant Transformation? JAMA Oncol. (IF 28.4) Pub Date : 2023-11-16 Bishal Gyawali,Garth W Strohbehn